

Supplemental Materials

Targeting the gut microbiome in allogeneic hematopoietic stem cell transplantation

Contents

Supplemental analyses	1
Patient microbiome at baseline	1
Conditioning and GM composition	1
donor microbiome composition and aGvHD	1
Linear model performance at aGvHD onset	2
functional differences between aGvHD cases and controls	3
In silico screening	3
Bibliography	5

List of Figures

S1	Comparison of donor and patient gut microbiomes	1
S2	GM composition and the use of cyclosporine	1
S3	Donor gut microbiome biological safety level	2
S4	ROC analysis of the aGvHD onset linear model	2
S5	Co-exclusion by and co-occurrence with QPS species	4
S6	Co-exclusion and co-occurrence between QPS species	5

List of Tables

S1	Predicted functional differences between aGvHD and non-aGvHD microbiomes	3
S2	Studies used for co-exclusion analysis	3

Supplemental analyses

Patient microbiome at baseline

Data set ERP017899 comprises baseline GM samples of 48 patients prior to allo-HSCT, as well as 16 donor GM samples. We used it to project GM composition differences between donors and patients. Other than the species diversity which was reported in [1], the strict anaerobe proportion also reaches significance, Fig. S1.




Figure S1: Comparison of donor and patient gut microbiomes. Data set ERP017899, 48 patients at baseline and 16 donors. Numbers reflect Wilcoxon signed rank test p-values.

Conditioning and GM composition

The use of the immunosuppressant cyclosporine, which in data set ERP017899 is mutually exclusive with the use of tacrolimus, is correlated with the over-representation of gram-positive bacteria, Fig. 2.




Figure S2: GM composition and the use of cyclosporine. Data set ERP017899, baseline samples of 41 patients who underwent allo-HSCT. Numbers reflect Wilcoxon signed rank test p-values.

donor microbiome composition and aGvHD

Data set ERP017899 provides for 15 donors microbiome samples with associated patient aGvHD status. None of the tested microbiome phenotypes reaches significance, but there is a trend of higher inferred average biological

safety level in association with aGvHD, Fig. 3.




Figure S3: Donor gut microbiome biological safety level. Data set ERP017899, 15 donors with associated patient GvHD status. Numbers reflect Wilcoxon signed rank test p-values.

Linear model performance at aGvHD onset

The linear model from figure 6 as applied to the originating combined “onset” dataset, can be scored according to a receiver operating characteristic (ROC) model, since the response variable is binary, Fig. S4.




Figure S4: ROC analysis of the aGvHD onset linear model. Combination of datasets, 68 subjects, 80 samples.

functional differences between aGvHD cases and controls

Table S1: Predicted functional differences between aGvHD and non-aGvHD microbiomes. Tukey honest significant difference test results on univariate linear models of predicted gene relative abundance. Comparison: aGvHD - non-aGvHD. ec: enzyme commission number. adiA: biodegradative arginine decarboxylase, mceE: methylmalonyl-CoA epimerase, mmdA: methylmalonyl-CoA carboxyltransferase, mutA: methylmalonyl-CoA mutase, padI: aromatic acid decarboxylase, speB: agmatine ureohydrolase, tnaB: tryptophan permease

metabolite	gene	ec	metabolism	diff	pAdj	sign
polyamines	adiA	4.1.1.19	arginine catabolism	-0.70	1.1e-04	***
	speB	3.5.3.11	arginine catabolism	-0.40	6.2e-05	***
AhR ligands	padI	4.1.1.28	tryptophan catabolism	-0.69	3.8e-05	***
	tnaB	-	tryptophan catabolism	-0.49	2.3e-03	**
propionate	mutA	5.4.99.2	succinate pathway	-0.41	2.0e-03	**
	mceE	5.1.99.1	succinate pathway	-0.42	9.2e-04	***
	mmdA	2.1.3.1	succinate pathway	-0.30	3.4e-04	***

In silico screening

To investigate if qualified presumption of safety (QPS) species could be of therapeutic interest, we computed pairwise χ^2 tests for all QPS species with mortality and aGvHD case associated species, Fig. 7, main manuscript. Fig. S5 provides the same analysis for control associated species and Fig. S6 provides pairwise χ^2 tests results between QPS species, the former to assess respect of control associated species and the latter to assess compatibility of QPS species for combination therapy.

The following large scale 16S microbiome studies, in addition to the studies listed in main manuscript Table 1, were used in the co-exclusion and co-occurrence analyses, Table S2.

Table S2: Studies used for co-exclusion analysis. 16S: variable regions sequenced. *: unpublished

SRA	16S	samples	publication
SRP062005	V4	stool	[2]
SRP076743	V4	stool	[3]
ERP009494	V3-V4	stool	[4]
SRP040765	V4	lower gut biopsies, stool	[5]
SRP104731	V4	stool	[6]
ERP006339	V4	stool	[7]
SRP070848	V4	sputum	[8]
SRP060025	V4-V5	sputum	[9]
SRP043334	V1-V2	sputum	[10]
SRP087648	V4	stool	[11]
SRP064975	V3-V4	lower gut biopsies	[12]
ERP012803	V4	stool	[13]
SRP063707	V1-V3	skin	[14]
SRP097785	V4	stool	[15]
SRP068187	V4	serum	[16]
SRP068473	V4	stool	[17]
SRP076281	V4	stool	[18]
SRP077299	V4	sputum	[19]
ERP013984	V4	eye, skin	[20]
SRP057700	V1-V2	stool	[21]
SRP090628	V4	stool	[22]
SRP154244	V4	gastric mucosa	*
ERP023753	V4	gastric mucosa	[23]
SRP200169	V3-V4	gastric mucosa	*
SRP070925	V3-V4	gastric mucosa	*
ERP024440	V1-V2	gastric mucosa	[24]
ERP023334	V1-V2	gastric mucosa	[25]
SRP128749	V3-V4	gastric mucosa	[26]
SRP172818	V3-V4	gastric mucosa	*
SRP165213	V3-V4	gastric mucosa	[27]




Figure S5: Co-exclusion by and co-occurrence with QPS species. Putative inhibition is in shades of red, potential synergy in shades of green. White reflect neutrality or too little combined prevalence to make a call. Genera are abbreviated as follows: **Bcl.:** *Bacillus*, **Bf.:** *Bifidobacterium*, **Gb.:** *Geobacillus*, **Lcn.:** *Leuconostic*, **Lctb.:** *Lactobacillus*, **Lctc.:** *Lactococcus*, **Pd.:** *Pediococcus*, **S.:** *Streptococcus*.




Figure S6: Co-exclusion and co-occurrence between QPS species. Putative inhibition is in shades of red, potential synergy in shades of green. White reflect neutrality or too little combined prevalence to make a call. Genera are abbreviated as follows: **Bcl.:** *Bacillus*, **Bf.:** *Bifidobacterium*, **Gb.:** *Geobacillus*, **Lcn.:** *Leuconostoc*, **Lctb.:** *Lactobacillus*, **Lctc.:** *Lactococcus*, **Pd.:** *Pediococcus*, **S.:** *Streptococcus*.

Bibliography

- [1] C Liu, D N Frank, M Horch, S Chau, D Ir, E A Horch, K Tretina, K van Besien, C A Lozupone, and V H Nguyen. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. *Bone marrow transplantation*, 52(12):1643–1650, December 2017. doi: 10.1038/bmt.2017.200.
- [2] Nielson T Baxter, Mack T Ruffin, Mary A M Rogers, and Patrick D Schloss. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine*, 8(1):37, April 2016. doi: 10.1186/s13073-016-0290-3.
- [3] Jacobo de la Cuesta-Zuluaga, Noel T Mueller, Vanessa Corrales-Agudelo, Eliana P Velásquez-Mejía, Jenny A

- Carmona, José M Abad, and Juan S Escobar. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. *Diabetes Care*, 40(1):54–62, January 2017. doi: 10.2337/dc16-1324.
- [4] Mária Džunková, Andrés Moya, Jorge F Vázquez-Castellanos, Alejandro Artacho, Xinhua Chen, Ciaran Kelly, Giuseppe D'Auria, and Hideyuki Tamaki. Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in *Clostridium difficile* Infection. *mSphere*, 1(3):e00101–16, June 2016. doi: 10.1128/mSphere.00101-16.
- [5] Dirk Gevers, Subra Kugathasan, Lee A Denson, Yoshiki Vázquez-Baeza, Will Van Treuren, Boyu Ren, Emma Schwager, Dan Knights, Se Jin Song, Moran Yassour, Xochitl C Morgan, Aleksandar D Kostic, Chengwei Luo, Antonio González, Daniel McDonald, Yael Haberman, Thomas Walters, Susan Baker, Joel Rosh, Michael Stephens, Melvin Heyman, James Markowitz, Robert Baldassano, Anne Griffiths, Francisco Sylvester, David Mack, Sandra Kim, Wallace Crandall, Jeffrey Hyams, Curtis Huttenhower, Rob Knight, and Ramnik J Xavier. The Treatment-Naive Microbiome in New-Onset Crohn's Disease. *Cell host & microbe*, 15(3):382–392, March 2014. doi: 10.1016/j.chom.2014.02.005.
- [6] James J Goedert, Gieira Jones, Xing Hua, Xia Xu, Guoqin Yu, Roberto Flores, Roni T Falk, Mitchell H Gail, Jianxin Shi, Jacques Ravel, and Heather Spencer Feigelson. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. *Journal of the National Cancer Institute*, 107(8), August 2015. doi: 10.1093/jnci/djv147.
- [7] Julia K Goodrich, Jillian L Waters, Angela C Poole, Jessica L Sutter, Omry Koren, Ran Blekhman, Michelle Beaumont, William Van Treuren, Rob Knight, Jordana T Bell, Timothy D Spector, Andrew G Clark, and Ruth E Ley. Human genetics shape the gut microbiome. *Cell*, 159(4):789–799, November 2014. doi: 10.1016/j.cell.2014.09.053.
- [8] Andrea Hahn, Amit Sanyal, Geovanny F Perez, Anamaris M Colberg-Poley, Joseph Campos, Mary C Rose, and Marcos Pérez-Losada. Different next generation sequencing platforms produce different microbial profiles and diversity in cystic fibrosis sputum. *Journal of Microbiological Methods*, 130:95–99, November 2016. doi: 10.1016/j.mimet.2016.09.002.
- [9] Deborah A Hogan, Sven D Willger, Emily L Dolben, Thomas H Hampton, Bruce A Stanton, Hilary G Morrison, Mitchell L Sogin, Julianna Czum, and Alix Ashare. Analysis of Lung Microbiota in Bronchoalveolar Lavage, Protected Brush and Sputum Samples from Subjects with Mild-To-Moderate Cystic Fibrosis Lung Disease. *PLoS ONE*, 11(3), 2016. doi: 10.1371/journal.pone.0149998.
- [10] Emily J Johnson, Edith T Zemanick, Frank J Accurso, Brandie D Wagner, Charles E Robertson, and J Kirk Harris. Molecular Identification of *Staphylococcus aureus* in Airway Samples from Children with Cystic Fibrosis. *PLoS ONE*, 11(1), 2016. doi: 10.1371/journal.pone.0147643.t002.
- [11] S Khanna, E Montassier, B Schmidt, R Patel, D Knights, D S Pardi, and P C Kashyap. Gut microbiome predictors of treatment response and recurrence in primary *Clostridium difficile* infection. *Alimentary Pharmacology & Therapeutics*, 44(7):715–727, August 2016. doi: 10.1111/apt.13750.
- [12] Yingying Lu, Jing Chen, Junyuan Zheng, Guoyong Hu, Jingjing Wang, Chunlan Huang, Lihong Lou, Xingpeng Wang, and Yue Zeng. Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas. *Scientific Reports*, 6:26337, May 2016. doi: 10.1038/srep26337.
- [13] Daniel McDonald, Embriette Hyde, Justine W Debelius, James T Morton, Antonio Gonzalez, Gail Ackermann, Alexander A Aksenov, Bahar Behsaz, Caitriona Brennan, Yingfeng Chen, Lindsay DeRight Goldsich, Pieter C Dorrestein, Robert R Dunn, Ashkaan K Fahimipour, James Gaffney, Jack A Gilbert, Grant Gogul, Jessica L Green, Philip Hugenholtz, Greg Humphrey, Curtis Huttenhower, Matthew A Jackson, Stefan Janssen, Dilip V Jeste, Lingjing Jiang, Scott T Kelley, Dan Knights, Tomasz Kosciolk, Joshua Ladau, Jeff Leach, Clarisse Marotz, Dmitry Meleshko, Alexey V Melnik, Jessica L Metcalf, Hosein Mohimani, Emmanuel Montassier, Jose Navas-Molina, Tanya T Nguyen, Shyamal Peddada, Pavel Pevzner, Katherine S Pollard, Gholamali Rahnavard, Adam Robbins-Pianka, Naseer Sangwan, Joshua Shorenstein, Larry Smarr, Se Jin Song, Timothy Spector, Austin D Swafford, Varykina G Thackray, Luke R Thompson, Anupriya Tripathi, Yoshiki Vázquez-Baeza, Alison Vrbanc, Paul Wischmeyer, Elaine Wolfe, Qiyun Zhu, American Gut Consortium, and Rob Knight. American Gut: an Open Platform for Citizen Science Microbiome Research. *mSystems*, 3(3), May 2018. doi: 10.1128/mSystems.00031-18.

- [14] Jacquelyn S Meisel, Geoffrey D Hannigan, Amanda S Tyldsley, Adam J SanMiguel, Brendan P Hodkinson, Qi Zheng, and Elizabeth A Grice. Skin Microbiome Surveys Are Strongly Influenced by Experimental Design. *Journal of Investigative Dermatology*, 136(5):947–956, May 2016. doi: 10.1016/j.jid.2016.01.016.
- [15] Elin Org, Yuna Blum, Silva Kasela, Margarete Mehrabian, Johanna Kuusisto, Antti J Kangas, Pasi Soininen, Zeneng Wang, Mika Ala-Korpela, Stanley L Hazen, Markku Laakso, and Aldons J Lusis. Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. *Genome Biology*, 18(1):70, April 2017. doi: 10.1186/s13059-017-1194-2.
- [16] Alba Santiago, Marta Pozuelo, Maria Poca, Cristina Gely, Juan Camilo Nieto, Xavier Torras, Eva Román, David Campos, Guillaume Sarrabayrouse, Silvia Vidal, Edilmar Alvarado-Tapias, Francisco Guarner, German Soriano, Chaysavanh Manichanh, and Carlos Guarner. Alteration of the serum microbiome composition in cirrhotic patients with ascites. *Scientific Reports*, 6:25001, April 2016. doi: 10.1038/srep25001.
- [17] Anna Maria Seekatz, Krishna Rao, Kavitha Santhosh, and Vincent Bensen Young. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent *Clostridium difficile* infection. *Genome Medicine*, 8(1):47, April 2016. doi: 10.1186/s13073-016-0298-8.
- [18] Kelly A Shaw, Madeline Bertha, Tatyana Hofmekler, Pankaj Chopra, Tommi Vatanen, Abhiram Srivatsa, Jarod Prince, Archana Kumar, Cary Sauer, Michael E Zwick, Glen A Satten, Aleksandar D Kostic, Jennifer G Mülle, Ramnik J Xavier, and Subra Kugathasan. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. *Genome Medicine*, 8(1):599, July 2016. doi: 10.1186/s13073-016-0331-y.
- [19] Meera K Shenoy, Shoko Iwai, Din L Lin, William Worodria, Irene Ayakaka, Patrick Byanyima, Sylvia Kaswabuli, Serena Fong, Stephen Stone, Emily Chang, J Lucian Davis, Ali Ahmad Faruqi, Mark R Segal, Laurence Huang, and Susan V Lynch. Immune Response and Mortality Risk Relate to Distinct Lung Microbiomes in HIV-Pneumonia Patients. *American journal of respiratory and critical care medicine*, pages rccm.201603–0523OC, July 2016. doi: 10.1164/rccm.201603-0523OC.
- [20] Hakdong Shin, Kenneth Price, Luong Albert, Jack Dodick, Lisa Park, and Maria Gloria Dominguez-Bello. Changes in the Eye Microbiota Associated with Contact Lens Wearing. *mBio*, 7(2):e00198, March 2016. doi: 10.1128/mBio.00198-16.
- [21] Joshua S Son, Ling J Zheng, Leahana M Rowehl, Xinyu Tian, Yuanhao Zhang, Wei Zhu, Leighann Litcher-Kelly, Kenneth D Gadow, Grace Gathungu, Charles E Robertson, Diana Ir, Daniel N Frank, and Ellen Li. Comparison of Fecal Microbiota in Children with Autism Spectrum Disorders and Neurotypical Siblings in the Simons Simplex Collection. *PLoS ONE*, 10(10), 2015. doi: 10.1371/journal.pone.0137725.
- [22] Tommi Vatanen, Aleksandar D Kostic, Eva d’Hennezel, Heli Siljander, Eric A Franzosa, Moran Yassour, Raivo Kolde, Hera Vlamakis, Timothy D Arthur, Anu-Maaria Hämäläinen, Aleksandr Peet, Vallo Tillmann, Raivo Uibo, Sergei Mokurov, Natalya Dorshakova, Jorma Ilonen, Suvi M Virtanen, Susanne J Szabo, Jeffrey A Porter, Harri Lähdesmäki, Curtis Huttenhower, Dirk Gevers, Thomas W Cullen, Mikael Knip, DIABIMMUNE Study Group, and Ramnik J Xavier. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. *Cell*, 165(4):842–853, May 2016. doi: 10.1016/j.cell.2016.04.007.
- [23] Theresa Wan-Chen Yap, Han Ming Gan, Yin-Peng Lee, Alex Hwong-Ruey Leow, Ahmad Najib Azmi, Fritz Francois, Guillermo I Perez-Perez, Mun Fai Loke, Khean Lee Goh, and Jamuna Vadivelu. *Helicobacter pylori* Eradication Causes Perturbation of the Human Gut Microbiome in Young Adults. *PLoS ONE*, 11(3):e0151893, 2016. doi: 10.1371/journal.pone.0151893.
- [24] Ingeborg Klymiuk, Ceren Bilgiler, Alexander Stadlmann, Jakob Thannesberger, Marie-Theres Kastner, Christoph Högenauer, Andreas Püspök, Susanne Biowski-Frotz, Christiane Schrutka-Kölbl, Gerhard G Thallinger, and Christoph Steininger. The Human Gastric Microbiome Is Predicated upon Infection with *Helicobacter pylori*. *Frontiers in Microbiology*, 8:e2836–12, December 2017. doi: 10.3389/fmicb.2017.02508.
- [25] Bryony N Parsons, Umer Z Ijaz, Rosalinda D’Amore, Michael D Burkitt, Richard Eccles, Luca Lenzi, Carrie A Duckworth, Andrew R Moore, Laszlo Tiszlavicz, Andrea Varro, Neil Hall, and D Mark Pritchard. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of *Helicobacter pylori*-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. *PLoS Pathogens*, 13(11):e1006653, November 2017. doi: 10.1371/journal.ppat.1006653.

- [26] Xiaosun Liu, Li Shao, Xia Liu, Feng Ji, Ying Mei, Yiwen Cheng, Fengping Liu, Chongxian Yan, Lanjuan Li, and Zongxin Ling. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. *EBioMedicine*, 40:336–348, February 2019. doi: 10.1016/j.ebiom.2018.12.034.
- [27] Cong He, Chao Peng, Huan Wang, Yaobin Ouyang, Zhenhua Zhu, Xu Shu, Yin Zhu, and Nonghua Lu. The eradication of *Helicobacter pylori* restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. *Helicobacter*, 24(4):e12590, August 2019. doi: 10.1111/hel.12590.